Assertio provides the LGS Foundation $100,000 educational grant

Assertio Holdings announced that it has provided the LGS Foundation a $100,000 educational grant to assist in efforts to raise awareness of LGS and provide educational materials to the LGS community. In October, Assertio acquired an exclusive license for SYMPAZAN or clobazam oral film CIV, which is approved by the U.S. Food and Drug Administration FDA for the adjunctive treatment of seizures associated with LGS in patients two years of age or older.According to the LGS Foundation, Lennox-Gastaut Syndrome or LGS is a severe epilepsy syndrome. LGS is a rare disease, about 50,000 people in the United States have LGS. It is generally diagnosed between the ages of 3 and 5, but some people aren’t correctly diagnosed until much later. People with LGS may have many different types of seizures, and the condition can be complex to manage. Some people with LGS also experience cognitive and behavioral challenges.